Evaluation of a displacement assay with tamoxifen as prognostic indicator in breast-cancer patients with estrogen-receptor-positive tumors

International Journal of Cancer

Volumn 73, Issue 4, 1997, Pages 486-491

  Levin, Emanuel ^a   Actis, Andrea M ^a   Caruso, Silvana ^a   Gass, Hugo ^b   Romero, Raquel ^c   Qualeta, Nicolás ^d   Levin, Rosa W ^d  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^b Hospital de Tigre   (Argentina)

^c Hospital Velez Sarsfield   (Argentina)

^d Hospital General De Agudos Teodoro Alvarez   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR; TAMOXIFEN;

ARTICLE; BREAST CANCER; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CARCINOGENESIS; DATA ANALYSIS; GENE EXPRESSION; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; QUANTITATIVE DIAGNOSIS; RECEPTOR BINDING; REMISSION; SURVIVAL RATE;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; ESTRADIOL; ESTROGEN ANTAGONISTS; FEMALE; HUMANS; NEOPLASM PROTEINS; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TAMOXIFEN;

EID: 0031437991     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19971114)73:4<486::AID-IJC5>3.0.CO;2-W     Document Type: Article

References (27)

1. ACTIS, A.M., CARUSO, S.P. and LEVIN, E., Estrogen-receptor isoforms and progestin hormone dependence in a mouse mammary-tumor model. Int. J. Cancer, 58, 668-671 (1994).
2. ACTIS, A.M., DORFMAN, V., CARUSO, S. and LEVIN, E., Modificaciones farmacológicas de receptores a estrógenos y a progesterona en útero de ratones (Estrogen- and progesterone-receptor pharmacological modifications in mouse uterus). 41 Reunión Científica Sociedad Argentina de Investigacón Clínica. Medicina, 56, 552 (Abstract) (1996).
3. ARONICA, S.M., KRAUS, W.L. and KATZENELLENBOGEN, B.S., Estrogen activation via cAMP signaling pathway: stimulation of adenylate cyclase and cAMP-regulated gene transcription. Proc. nat. Acad. Sci. (Wash.), 91, 8517-8521 (1994).
4. BALTUCH, G.H. and YONG, V.W., Signal transduction for proliferation of glioma cells occurs predominantly through a protein-kinase-C-mediated pathway. Brain Res., 710, 43-49 (1996).
5. CABOT, M., ZHANG, Z.C. and GIULIANO, A.E., Tamoxifen elicits rapid transmembrane lipid signal responses in human breast-eancer cells. Breast Cancer Res. Treat., 36, 299-306 (1995).
6. CHURCH LANDEL, C., KUSHNER, P.J. and GREENE, G.L., The interaction of human estrogen receptor with DNA is modulated by receptor-associated proteins. Mol. Endocrinol., 8, 1407-1419 (1994).
7. CLARK, G.M., WENGER, C.R., BEARDSLEE, S., OWENS, M.A., POUNDS, G., OLDAKER, T., VENDELY, P., PAUDIAN, R.M., HARRINGTON, D., and MCGUIRE, W.L., How to integrate steroid-hormone-receptor, flow-cytometric and other prognostic information in regard to primary breast cancer. Cancer, 71, 2157-2162 (1993).
8. CUSTODIO, J.B.A., DINIS, T.C.P., ALAMEIDA, L.M. and MADEIRA, V.M.C., Tamoxifen and hydroxytamoxifen as inhibitors of lipid peroxidation. Evidence for peroxyl radical scavenging activity. Biochem. Pharmacol., 47, 1989-1998 (1994).
9. DOWSETT, M., MAKRIS, A., ELLIS, P., JOHNSTON, S.D.R., SALTER, J., DETRE, S., HUMPHRIES, S., SACCANI-JOTTI, E., POWLES, T.J. and SMITH, I.E., Oncogene products and other diagnostic markers in human breast-cancer patients. In: L. Castagnetta, Y. Nenci and H.L. Bradlow (eds.), Basis for cancer management. Vol. 784, pp. 403-411. Annals N.Y. Acad. Sci., New York (1996).
10. FAWELL, S., WHITE, R., HOARE, S., SYDENHAM, S., PAGE, M. and PARKER, M., Inhibition of estrogen-receptor-DNA binding to the "pure" anti-estrogen ICI 164,384 appears to be mediated by impaired receptor dimerization. Proc. nat. Acad. Sci. (Wash.), 870, 6883-6887 (1990).
11. FISHER, B., OSBORNE, C.K., MARGOLESE, R. and BLOOMER, W., Neoplasms of the breast. In: J.F. Holland, E. Frei, R.C. Bast, D.W. Kufe, D.L. Morton and R.R. Weichselbaum (eds.), Cancer medicine (3rd ed.), p. 1730, Lea and Febiger, Philadelphia (1993).
12. GREENBERG, D.A., CARPENTER, C.L. and MESSING, R.O., Calcium-channel-antagonist properties of the anti-neoplastic anti-estrogen tamoxifen in the PC 12 neurosecretory cell line. Cancer Res., 47, 70-74 (1987).
13. JENSEN, E.V., GREENE, G.L., CLOSS, L.E., DESOMBRE, E.R. and NADJI, M., Receptor reconsidered: a 20-year perspective. Recent Prog. Horm. Res., 38, 1-140 (1982).
14. KISS, Z., Tamoxifen stimulates phospholipase-D activity by an estrogen-receptor-independent mechanism. FEBS Lett., 355, 173-177 (1994).
15. LANDERS, J.P. and SPELSBERG, T.C., New concepts in steroid-hormone action: transcription factors, proto-oncogenes, and the cascade model for steroid regulation of gene expression. Crit. Rev. Eukar. Gene Expression, 2, 19-63 (1992).
16. LE GOFF, P., MONTANO, M.M., SCODIN, D.J. and KATZENELLENBOGEN, B.S., Phosphorylation of the human estrogen receptor. J. biol. Chem., 269, 4458-4466 (1994).
17. LEVIN, E., CARUSO, S. and ACTIS, A., Functional expressions of estrogen receptors in experimental and human mammary tumors. Endocrine-Related Cancer, 2, 111-113 (1995).
18. LEVIN, E., TOMCHINSKY, S. and LOPEZ, S.J., Displacement by tamoxifen of the estradiol-estrogen-receptor binding: a functional assay for breast-cancer studies. J. Steroid Biochem. Mol. Biol., 37, 681-686 (1990).
19. MCGUIRE, W. and CLARK, G., Role of progesterone receptors in breast cancer. Semin. Oncol., 12, 12-16 (1985).
20. MCGUIRE, W.L., Quantitation of estrogen receptor in mammary carcinoma. In: B.W. O'Malley and J.G. Hardman (eds.), Methods in enzymology, pp. 248-254, Academic Press, New York (1975).
21. METZGER, D., BERRY, M., ALI, S. and CHAMBON, P., Effects of antagonists on DNA-bindins properties of the human estrogen receptor in vitro and in vivo. Mol. Endocrinol., 9, 579-591 (1995).
22. SABBAH, M., GOUILLIEUX, F., SOLA, B., REDDEUILH, G. and BAULIEU, E.E., Structural differences between the hormone and anti-hormone estrogen-receptor complexes bound to the hormone-response element. Proc. nat. Acad. Sci. (Wash.), 88, 390-394 (1991).
23. SELVIN, S., Statistical analysis of epidemiology data. Oxford University Press, New York (1991).
24. STEWART, A.G., WESTLEY, B.R. and MAY, F.E.B., Modulation of the proliferative response of breast-cancer cells to growth factors by estrogen. Brit. J. Cancer, 66, 640-648 (1992).
25. UZIELY, B., LEWIN, A., BRUFMAN, G., DOREMBUS, D. and MOR-JOSEF, S., The effect of tamoxifen on the endometrium. Breast Cancer Res. Treat., 26, 101-105 (1993).
26. WEBB, P., LOPEZ, G.N., UHT, R.M. and KUSHNER, P.J., Tamoxifen activation of the estrogen-receptor/AP-1 pathway: potential origin for the cell-specific estrogen-like effects of anti-estrogens. Mol. Endocrinol., 9, 443-46 (1995).
27. WIEBE, V.J., OSBORNE, C.K., FUQUA, S.A.W. and DEGREGORIO, M.W., Tamoxifen resistance in breast cancer. Crit. Rev. Oncol. Hematol., 14, 173-188 (1993).